Product Liability

FDA Issues Safety Alert on Avandia

FDA Issues Safety Alert on Avandia The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related […]

Driving while asleep among risks of sleeping pills

Driving while asleep among risks of sleeping pills The FDA recently demanded stricter warnings on the labels of various prescription sleep medications in response to some alarming side-effects. Most notably, some sleeping pill patients have been driving in their sleep; in addition to sleep-driving, those on sleep medications are also completing other “complicated activities” while […]

FDA Requests Label Change for All Sleep Disorder Drug Products

FDA Requests Label Change for All Sleep Disorder Drug Products The U.S. Food and Drug Administration (FDA) has requested that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen their product labeling to include stronger language concerning potential risks. These risks include severe allergic reactions and complex […]

Zyprexa & Diabetes (Olanzapine)

Zyprexa & Diabetes (Olanzapine) Injured by Zyprexa? Side effects of this antipsychotic drug include diabetes, weight gain, hyperglycemia, pancreatitis, and diabetic ketoacidosis. Zyprexa Risks The following are the risks and side effects associated with Zyprexa therapy. This list is not exhaustive. From the FDA web site, Zyprexa’s risks include: A life-threatening nervous system problem called neuroleptic […]

Serious Eye Infections Prompt Bausch & Lomb To Withdraw ReNu MoistureLoc® Contact Lens Solution From Market

Serious Eye Infections Prompt Bausch & Lomb To Withdraw ReNu MoistureLoc® Contact Lens Solution From Market Damage May Require Corneal Transplant Patients who wear soft contact lenses should be aware of an increasing number of reports of rare but serious fungal eye infection that can cause permanent blindness. The infection, Fusarium keratitis, has been reported […]

FDA Updates Regarding Voluntary Market Withdrawal of Bausch & Lomb ReNu MoistureLoc® Contact Lens Solution

FDA Updates Regarding Voluntary Market Withdrawal of Bausch & Lomb ReNu MoistureLoc® Contact Lens Solution Update on Serious Eye Infections Associated with Soft Contact Lens Use and Contact Lens Solution May 5, 2006. As reported in the MMWR, patients with confirmed cases of Fusarium keratitis have reported using various contact lens cleaning solutions including various types of ReNu […]

Lilly and Plaintiffs’ Attorneys Enter Into an Agreement in Principle to Settle Majority of Zyprexa® Product Liability Litigation

Bausch & Lomb Asks Retailers to Remove U.S.-Manufactured ReNu® with MoistureLoc® from Shelves Bausch & Lomb (NYSE:BOL) today asked U.S. retailers to remove ReNu® with MoistureLoc® from their shelves temporarily, and recommended that consumers switch to another lens care solution for the time being, until the investigation of reports of fungal keratitis infections among contact […]

Lilly and Plaintiffs’ Attorneys Enter Into an Agreement in Principle to Settle Majority of Zyprexa® Product Liability Litigation

Lilly and Plaintiffs’ Attorneys Enter Into an Agreement in Principle to Settle Majority of Zyprexa® Product Liability Litigation Eli Lilly and Company announced today that it has entered into an agreement in principle with plaintiffs’ attorneys involved in Zyprexa liability litigation to settle a majority of the claims against Lilly relating to the medication. When […]

FDA Issues Public Health Advisory for Antipsychotic Drugs used for Treatment of Behavioral Disorders in Elderly Patients

FDA Issues Public Health Advisory for Antipsychotic Drugs used for Treatment of Behavioral Disorders in Elderly Patients The Food and Drug Administration (FDA) today issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., “off-label”) use of certain drugs called “atypical antipsychotic drugs.” […]

New FDA Labeling for Pfizer’s Celebrex and All Other NSAIDs to Reflect Similar Cardiovascular Profile

New FDA Labeling for Pfizer’s Celebrex and All Other NSAIDs to Reflect Similar Cardiovascular Profile Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all […]

FREE CASE EVALUATION

No fee unless you receive compensation!

"*" indicates required fields

Hidden

Next Steps: Sync an Email Add-On

To get the most out of your form, we suggest that you sync this form with an email add-on. To learn more about your email add-on options, visit the following page (https://www.gravityforms.com/the-8-best-email-plugins-for-wordpress-in-2020/). Important: Delete this tip before you publish the form.
Address*